Sun Pharmaceutical Industries Ltd.

Sun Pharmaceutical Industries’ wholly owned subsidiary -- Sun Pharma Canada Inc. has received Health Canada’s approval for WINLEVI (clascoterone cream 1%). WINLEVI is the first and only androgen receptor inhibitor indicated for the topical treatment of acne vulgaris (acne) in patients 12 years of age and older, and the newest Health Canada-approved formulation to target the hormonal component of acne for Canadian patients in 40 years.

WINLEVI is thought to inhibit the effects of androgen receptors in cells of the sebaceous glands (oil producing glands in the skin) to help reduce sebum (oil) production and inflammatory cytokines and thus inhibits the androgen cascade.

Instead of a topical approach to acne treatment that focuses on follicular hyperkeratinization, reducing inflammation or exerting antibacterial effects, WINLEVI targets the androgen receptor in the skin to tackle sebum production and inflammation. WINLEVI will be available in Canada this fall.

Sun Pharmaceutical Industries is the world's fourth largest specialty generic pharmaceutical company and India's top pharmaceutical company.